INTRODUCTION {#s1}
============

Cancer is a major health problem all over the world, as the second leading and leading cause of death in the US and China, respectively \[[@R1], [@R2]\]. Although diagnostic and treatment modalities have been developed for decades, the average five-year survival rate for cancer patients is still very low. The main reasons for the high cancer mortality rate are the lack of effective detection methods at early stages and the high recurrence rate. Therefore, the study of diagnostic and prognostic markers in cancer patients has major clinical significance.

Long noncoding RNAs (lncRNAs) are RNA molecules ranging from 200 nucleotides to 100 kilobases in length, without protein-coding abilities \[[@R3], [@R4]\]. LncRNAs are deregulated in a variety of diseases, including cancer \[[@R5]--[@R8]\]. These differentially expressed RNAs participate in various regular biological processes at the transcriptional and posttranscriptional levels \[[@R5]\]. LncRNAs can regulate gene expression through multiple approaches, such as by recruiting transcription factors or directly binding to proteins, RNA and DNA \[[@R5]\]. Many lncRNAs have been reported to participate in tumorigenesis, tumor progression and cancer prognosis \[[@R9]--[@R12]\].

Homeobox A transcript at the distal tip (*HOTTIP*) is a 3,764-nucleotide-long lncRNA encoded by a gene at the 5' end of the *HOXA* cluster (chromosome 7p15.2) \[[@R4]\]. *HOTTIP* is upregulated in various carcinomas, such as lung carcinoma \[[@R13]\], gastric carcinoma (GC) \[[@R9]\], pancreatic carcinoma \[[@R11]\], hepatocellular carcinoma (HCC) \[[@R8]\] and squamous cell carcinoma \[[@R14]\]. In addition, *HOTTIP* levels have been associated with tumor pathological characteristics and patient prognostic outcomes \[[@R10]--[@R14]\]. These findings suggest that *HOTTIP* could be developed as a potential diagnostic and prognostic biomarker for human cancers. However, individual studies may be inaccurate or inadequate due to limitations of the sample sizes or research programs. Therefore, in this study, we collected all relevant publications and conducted a meta-analysis to explore the relationship between *HOTTIP* expression and cancer clinical outcomes, and to determine the potential of *HOTTIP* as a common predictive biomarker for metastasis and prognosis in cancer patients.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

Our initial search retrieved 327 potentially relevant papers from Embase, Web of Science, PubMed and the China National Knowledge Infrastructure (CNKI). Following the removal of duplicates, 290 records were preserved. After the titles and abstracts were screened, 39 full-text articles remained. However, 30 of them were excluded due to incomplete data. Ultimately, nine studies met the eligibility criteria and were included in the meta-analysis \[[@R8]--[@R12], [@R13], [@R15]--[@R17]\]. A flow diagram of the study selection process is shown in Figure [1](#F1){ref-type="fig"}.

![Flow diagram of the literature search and selection](oncotarget-08-59563-g001){#F1}

In total, 800 patients were included in this study. Eight studies came from China and one came from Switzerland. Cancers of seven carcinoma types were included in our study: HCC, osteosarcoma (OSA), colorectal cancer (CRC), pancreatic cancer (PC), GC, tongue squamous cell carcinoma (TSCC) and breast cancer (BC). In all of the studies, lncRNA *HOTTIP* expression was detected by quantitative reverse transcription PCR (qRT-PCR). The main features of the nine studies that qualified for the present meta-analysis are summarized in Table [1](#T1){ref-type="table"}.

###### Main characteristic of the eligible studies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study            Region        Tumor\   Sample size   Test method   Cut-off            *HOTTIP* expression   Outcome measure   Follow-up (months)                       
                                 type                                                                                                                                     
  ---------------- ------------- -------- ------------- ------------- ------------------ --------------------- ----------------- -------------------- ---- ---- ---- ---- -------------
  Quagliata 2014   Switzerland   HCC      52            qRT-PCR       ROC curve          NA                    NA                32                   NA   NA   20   OS   Over 80

  Ge\              China         HCC      48            qRT-PCR       ROC curve          NA                    NA                NA                   NA   NA   NA   OS   18 (5--72)
  2015                                                                                                                                                                    

  Li 2015          China         OSA      68            qRT-PCR       Median value       NA                    11                34                   NA   3    34   OS   Over 60

  Ren 2015         China         CRC      156           qRT-PCR       Median value       47                    27                77                   36   14   79   OS   46 (33--65)

  Wang 2015        China         PC       144           qRT-PCR       ROC curve          75                    NA                118                  10   NA   26   OS   Over 60

  Zhang 2015       China         TSCC     86            qRT-PCR       Median value       28                    7                 44                   18   1    42   OS   38 (23--60)

  Lian 2016        China         CRC      48            qRT-PCR       X-tile algorithm   21                    NA                32                   7    NA   16   NA   NA

  Ye 2016          China         GC       98            qRT-PCR       Median value       39                    NA                49                   29   NA   49   OS   Over 60

  Yang\            China         BC       100           qRT-PCR       Median value       32                    NA                50                   19   NA   50   OS   Over 100
  2017                                                                                                                                                                    
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ROC, receiver operating characteristic. NA, not applicable.

Relationship between increased *HOTTIP* expression and overall survival {#s2_2}
-----------------------------------------------------------------------

The relationship between *HOTTIP* expression and overall survival (OS) was evaluated in eight studies including 752 patients. No significant heterogeneity was observed among the studies (*I*^2^ = 0%, *P* = 0.922), so a fixed-effects model was used to pool the results. The pooled HR indicated that *HOTTIP* expression was negatively associated with OS (HR = 2.30, 95% confidence interval \[CI\]: 1.81--2.91, *P* \< 0.001, fixed-effects model) (Figure [2](#F2){ref-type="fig"}). To evaluate the robustness of the merged results, we conducted a sensitivity analysis by successively omitting each individual study. The results were not significantly affected by the exclusion of any individual study, indicating that the results of this meta-analysis were robust (Figure [3](#F3){ref-type="fig"}).

![Forest plot for the relationship between *HOTTIP* expression and OS](oncotarget-08-59563-g002){#F2}

![Sensitivity analysis for the meta-analysis](oncotarget-08-59563-g003){#F3}

Relationship between increased *HOTTIP* expression and clinicopathological parameters {#s2_3}
-------------------------------------------------------------------------------------

Six articles encompassing 632 patients evaluated lymph node metastasis (LNM) according to lncRNA *HOTTIP* expression. There was no significant heterogeneity among these studies (*I*^2^ = 0%, *P* = 0.964). Subsequently, a fixed-effects model was adopted to analyze the data (Figure [4](#F4){ref-type="fig"}, Table [2](#T2){ref-type="table"}). The odds ratio (OR) of LNM for the high *HOTTIP* expression group versus the low expression group was 2.40 (95% CI: 1.70--3.37, *P* \< 0.001).

![Forest plot for the relationship between *HOTTIP* expression and clinicopathological parameters](oncotarget-08-59563-g004){#F4}

###### Meta-analysis results on the association of increased *HOTTIP* expression with clinicopathological parameters

  Clinicopathological parameter                Patient number   OR (95% CI)         *P* value   Heterogeneity           
  -------------------------------------------- ---------------- ------------------- ----------- --------------- ------- -------
  Age (≥ 60 vs.\< 60)                          484              0.95 (0.65--1.41)   0.81        0.57            0.0%    0.902
  Gender (Male vs. Female)                     662              1.11 (0.80--1.55)   0.536       7.69            21.9%   0.261
  Clinical stage (III/IV vs. I/II)             488              3.28 (2.22--4.83)   \< 0.001    2.03            0.0%    0.731
  Differentiation (Poor vs. Well/moderately)   532              1.55 (1.03--2.32)   0.036       2.37            0.0%    0.667
  Lymph node metastasis (Yes vs. No)           632              2.40 (1.70--3.37)   \< 0.001    0.98            0.0%    0.964
  Distant metastasis (Yes vs. No)              310              3.30 (1.78--6.12)   \< 0.001    1.46            0.0%    0.481

Three studies described cancer patients with distant metastasis (DM). There was no heterogeneity among these studies (*I*^2^ = 0%, *P* = 0.481). Thus, a fixed-effects model was used to calculate the pooled result (Figure [4](#F4){ref-type="fig"}, Table [2](#T2){ref-type="table"}). The OR of DM was 3.30 for patients with high *HOTTIP* expression (95% CI: 1.78--6.12, *P* \< 0.001). These aggregated results suggested that cancer patients with high *HOTTIP* expression were more susceptible to LNM and DM than patients with low *HOTTIP* expression.

In addition, we found that high *HOTTIP* expression was positively associated with poor tumor differentiation (OR = 1.55, 95% CI: 1.03--2.32, *P* = 0.036) and a poor clinical stage (OR = 3.28, 95% CI: 2.22--4.83, *P* \< 0.001) (Figure [4](#F4){ref-type="fig"}, Table [2](#T2){ref-type="table"}). However, increased *HOTTIP* expression did not correlate significantly with age or gender (Figure [4](#F4){ref-type="fig"}, Table [2](#T2){ref-type="table"}). Due to insufficient data, we were unable to determine the association between high *HOTTIP* expression and other clinicopathological parameters.

Publication bias {#s2_4}
----------------

We performed Begg\'s funnel plot analysis to evaluate the publication bias. There was no obvious publication bias affecting the analysis of OS (*Pr*\>\|z\|=0.458), LNM (*Pr*\>\|z\|=0.851) or DM (*Pr*\>\|z\|=0.296) (Figure [5](#F5){ref-type="fig"}).

![Funnel plot analysis of potential publication bias in the meta-analysis\
(**A**) OS group; (**B**) LNM group; (**C**) DM group.](oncotarget-08-59563-g005){#F5}

DISCUSSION {#s3}
==========

*HOTTIP* is a 3,764-nucleotide-long lncRNA encoded by a gene at the homeobox A (*HOXA*) locus \[[@R4]\]. *HOTTIP* recruits histone-modifying enzymes to activate *HOX* gene transcription and inhibit tumor-suppressor gene expression \[[@R4], [@R18]\]. Therefore, *HOTTIP* has been considered as a carcinogenic factor, and overexpression of *HOTTIP* has been reported to promote tumor growth \[[@R13], [@R18]\]. We conducted this comprehensive meta-analysis to evaluate the relationship of lncRNA *HOTTIP* expression with prognostic results and clinicopathological parameters in cancer patients.

Nine eligible studies met the selection requirements of this meta-analysis. The data from tumor patients were processed according to OS, age, gender, clinical stage, differentiation, LNM and DM. Our results suggested that cancer patients with high *HOTTIP* expression in tumor tissues were more likely to exhibit poor tumor differentiation, a poor clinical stage, LNM and DM than patients with low *HOTTIP* expression. In addition, we found that increased *HOTTIP* levels were significantly and negatively associated with shorter OS times in tumor patients. Sensitivity analysis indicated that no single study impacted the overall results, suggesting that the pooled results were robust. Furthermore, no obvious publication bias or heterogeneity was observed among our included studies.

Many studies have demonstrated that *HOTTIP* may be an oncogenic lncRNA. *HOTTIP* was reported to influence HCC cell proliferation \[[@R8]\]. Knockdown of *HOTTIP* reduced *HOXA13* expression, and knockdown of *HOXA13* also reduced *HOTTIP* expression in HCC-derived cell lines \[[@R8]\]. Tsang and colleagues \[[@R19]\] found that downregulation of *HOTTIP* markedly reduced the expression of numerous *HOXA* genes and weakened liver cancer growth and metastasis both *in vivo* and *in vitro*. *HOTTIP* also was shown to be upregulated in human pancreatic ductal adenocarcinoma tissues and to promote pancreatic ductal adenocarcinoma cell proliferation, migration, invasion and resistance by regulating *HOXA13* \[[@R20]\]. However, another study in pancreatic cancer cells demonstrated that *HOTTIP* did not modulate *HOXA13* expression, but did regulate the expression of other *HOX* genes such as *HOXA1*, *HOXA9*, *HOXA10*, *HOXA11* and *HOXB2* \[[@R21]\]. In addition, Lian and coworkers \[[@R12]\] found that *HOTTIP* promoted CRC cell growth by silencing p21 expression. Furthermore, *HOTTIP* was reported to inhibit cell apoptosis and promote the progression of prostate cancer and lung cancer \[[@R13], [@R22]\]. These results may illustrate why high *HOTTIP* expression was significantly associated with a poor prognosis in cancer patients in this meta-analysis.

There are some limitations that should be noted for the current study. Firstly, most of the included cancer patients were from Chinese populations. Thus, our results need to be confirmed with more clinical data from other ethnic groups. Secondly, some HRs and their corresponding 95% CIs were extracted from Kaplan-Meier curves, and may have been less reliable than those obtained directly from articles. Thirdly, the number of original studies included in this meta-analysis was small. Fourthly, studies with positive results are more likely to be published than those with negative results. Thus, as a literature-based analysis, this study may have overestimated the association between high *HOTTIP* expression and clinical outcomes. Finally, many other factors may also influence OS, such as gender, age and treatment. Thus, the results of our meta-analysis should be confirmed in future studies.

In conclusion, our meta-analysis suggests that the upregulation of *HOTTIP* is a risk factor for poor clinical outcomes in diverse cancers, and could serve as a potential prognostic biomarker. Nevertheless, given the limitations described above, well-designed studies of particular carcinoma types and large sample sizes are needed to confirm the clinical utility of *HOTTIP*.

MATERIALS AND METHODS {#s4}
=====================

Literature search strategy {#s4_1}
--------------------------

We conducted a literature search in the online electronic databases of Embase, Web of Science, PubMed and CNKI (up to January 2, 2017). The search keywords and their combinations were: "HOTTIP OR Homeobox A transcript at the distal tip" AND "cancer OR carcinoma OR tumor OR tumour OR neoplasm". Only English and Chinese articles were included in this study.

Selection and exclusion criteria {#s4_2}
--------------------------------

The inclusion criteria of this meta-analysis were: (1) research on the association between *HOTTIP* and cancer prognosis, (2) division of patients into two groups: high or low *HOTTIP* expression, and (3) sufficient data for the computation of ORs or HRs with 95% CIs. The exclusion criteria for our meta-analysis were: (1) duplicate articles, (2) case reports, letters, expert opinions, editorials and reviews, and (3) studies without available data.

Data extraction {#s4_3}
---------------

Two investigators (Wei Li and Xinmei Kang) extracted and reviewed the data from the eligible studies independently. Another researcher (Ke Shi) resolved any disagreements. The collected data were as follows: first author\'s name, publication date, study region, tumor type, tumor stage, detection method for *HOTTIP* expression, criteria for high *HOTTIP* expression, sample size, total patient number, number of patients in the high *HOTTIP* and low *HOTTIP* groups, number of patients with LNM and DM in each group, survival analysis, follow-up period, HR and corresponding 95% CI. If the survival data were not shown directly in the article, Engauge Digitizer v.4.1 software was used to obtain them from the Kaplan-Meier curve, as previously described \[[@R23]\].

Statistical methods {#s4_4}
-------------------

STATA 12.0 software (Stata, College Station, Texas) was used to perform all statistical analyses in this study. Patients were separated into the high and low *HOTTIP* expression groups according to the original published articles. The heterogeneity among the included studies was judged with the *Q*-statistic test and the chi-squared test. A "Begg\'s funnel plot" was used to determine the potential publication bias. A fixed-effects model was used to analyze the pooled results when the included studies did not exhibit significant heterogeneity (*P* \> 0.1); otherwise, a random-effects model was employed (*P* \< 0.1). A sensitivity analysis was conducted to evaluate the robustness of the overall results. All *P*-values were determined with a two-tailed test, and *P* \< 0.05 was regarded as statistically significant.
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